Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

SAN DIEGO–()–Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors.

“We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in cancer treatment response, and our AMBROSIA food-as-medicine study. These programs are underpinned by important partnerships we have signed with Janssen, Kroger Health and Ginkgo Bioworks, which have furthered both our company’s strategic priorities and our technology,” said Stephanie Culler, CEO and Co-founder of Persephone Biosciences. “As Chair, Dan brings his vast experience as a serial entrepreneur, spanning both public and private biotechs, to our company. We look forward to benefiting from his wise counsel in the years to come as we collectively seek to fulfill Persephone’s clinical and commercial promise.”

“I’m thrilled to be joining Persephone, where Stephanie and her team have created an innovative biotech at the forefront of microbiome research and its practical applications to important and pressing adult and infant health needs,” said Daniel Bradbury, Chair of Persephone Biosciences. “In the short term, I hope to assist Persephone Consumer Health with the commercialization of its infant gut health products, where research has shown that a baby’s microbiome is integral to its healthy maturity, and where deficiencies are linked to higher levels of allergic disorders. Looking further ahead, I believe Persephone Therapeutics is positioned to sign further collaborations with marquee partners for its clinical plans, as well as progress its candidates for precision medicines into and through the clinic. It’s an exciting time to be joining Persephone and I’m looking forward to contributing to its success.”

Mr. Bradbury has over 35 years of experience leading global, fast-growing life sciences companies. Dan currently serves as Executive Chairman of Equillium (Nasdaq: EQ), a biopharmaceutical company he co-founded. In addition, Mr. Bradbury is a Managing Member of BioBrit, a life sciences consulting and investment firm. Previously, Dan held several senior positions at Amylin Pharmaceuticals, a biopharmaceutical company focused on diabetes and metabolic disorders, including as President and Chief Executive Officer, until its acquisition by Bristol-Myers Squibb Company in August 2012. Prior to joining Amylin, Mr. Bradbury worked at SmithKline Beecham Pharmaceuticals and its predecessor companies for ten years in various sales and marketing positions. Dan currently serves as a director of Castle Biosciences (NASDAQ: CSTL) and Intercept Pharmaceuticals (NASDAQ: ICPT) and additionally serves on the board of directors of a number of private companies and philanthropic organizations. In addition, Mr. Bradbury serves on the Keck Graduate Institute’s Board of Trustees and the University of California San Diego’s Rady School of Management Dean’s Advisory Council.

Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

Following today’s announcement, Persephone’s Board now consists of: Daniel Bradbury (Chair) (Managing Member BioBrit, LLC), Dr. Paul Grint (Executive Chairman, Codagenix Inc.), Véronique Riethuisen (Managing Director, VR Strategic Advisors LLC), Veronica Wu (Founder and Managing Partner at First Bight Ventures), and Dr. Leen Kawas (Managing General Partner of Propel Bio Partners).

About Persephone Biosciences

Persephone Biosciences is a biotechnology company reimagining patient health through the development of microbiome-based medicines. The company’s operations comprise Persephone Consumer Health and Persephone Therapeutics. Persephone Consumer Health is focused on adult and infant wellbeing, through the development of pioneered probiotics (My Baby Biome™ clinical study) and Food as Medicine (AMBROSIA clinical study). Persephone Therapeutics is targeting improved patient therapeutic response, with an initial focus on oncology treatment and prevention (ARGONAUT clinical study). The company was founded in 2017 by synthetic and metabolic engineers, Stephanie Culler, Ph.D., and Steve Van Dien, Ph.D. For more information, visit, or on Twitter and LinkedIn.


Recent Articles